225 related articles for article (PubMed ID: 21439088)
21. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.
Lee SH; Kim HJ; Kim WC
Asia Pac J Clin Oncol; 2016 Dec; 12(4):388-395. PubMed ID: 27461444
[TBL] [Abstract][Full Text] [Related]
22. CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance.
Aluwini S; van Rooij P; Hoogeman M; Bangma C; Kirkels WJ; Incrocci L; Kolkman-Deurloo IK
J Endourol; 2010 May; 24(5):865-9. PubMed ID: 20433370
[TBL] [Abstract][Full Text] [Related]
23. Disease control outcomes of stereotactic body radiation therapy or moderate hypo-fractionation for prostate cancer: Real-world experience at two Canadian centers.
Hu HP; Anagnostopoulos G; Gouran-Savadkoohi M; Dayes I; Ishkanian A; Hallock A; Lukka H; Quan K; Schnarr K; Cuthbert D; Goldberg M; Chang YM; Tsakiridis T
Prostate; 2024 Feb; 84(2):193-202. PubMed ID: 37880911
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
[TBL] [Abstract][Full Text] [Related]
25. A Multicenter Phase 2 study of Hypofractionated Stereostatic Boost in Intermediate Risk Prostate Carcinoma: A 5-Year Analysis of the CKNO-PRO Trial.
Pasquier D; Peiffert D; Nickers P; Maingon P; Pommier P; Lacornerie T; Martinage G; Tresch E; Lartigau E
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):116-123. PubMed ID: 31604131
[TBL] [Abstract][Full Text] [Related]
26. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer.
Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199
[TBL] [Abstract][Full Text] [Related]
27. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
[TBL] [Abstract][Full Text] [Related]
28. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
[TBL] [Abstract][Full Text] [Related]
29. High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low-Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients.
D'Agostino G; Franzese C; De Rose F; Franceschini D; Comito T; Villa E; Alongi F; Liardo R; Tomatis S; Navarria P; Mancosu P; Reggiori G; Cozzi L; Scorsetti M
Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e173-e178. PubMed ID: 27389021
[TBL] [Abstract][Full Text] [Related]
30. Treatment outcomes of postoperative ultra-hypofractionated stereotactic body radiotherapy in prostate cancer.
Ozyigit G; Onal C; Beduk Esen CS; Tilki B; Hurmuz P
Urol Oncol; 2023 May; 41(5):252.e1-252.e8. PubMed ID: 36631368
[TBL] [Abstract][Full Text] [Related]
31. Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer.
Markovina S; Weschenfelder DC; Gay H; McCandless A; Carey B; DeWees T; Knutson N; Michalski J
Pract Radiat Oncol; 2014; 4(6):430-6. PubMed ID: 25407866
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study.
Katz AJ; Kang J
Front Oncol; 2014; 4():240. PubMed ID: 25229051
[TBL] [Abstract][Full Text] [Related]
33. First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.
Dixit A; Tang C; Bydder S; Kedda MA; Vosikova E; Bharat C; Gill S
J Med Radiat Sci; 2017 Sep; 64(3):180-187. PubMed ID: 28271639
[TBL] [Abstract][Full Text] [Related]
34. Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes.
Fuller DB; Falchook AD; Crabtree T; Kane BL; Medbery CA; Underhill K; Gray JR; Peddada A; Chen RC
Eur Urol Oncol; 2018 Dec; 1(6):540-547. PubMed ID: 31158102
[TBL] [Abstract][Full Text] [Related]
35. SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.
Rucinska M; Kieszkowska-Grudny A; Nawrocki S
Strahlenther Onkol; 2016 Jul; 192(7):449-57. PubMed ID: 27221312
[TBL] [Abstract][Full Text] [Related]
36. A Phase I/II Study of Stereotactic Hypofractionated Once-weekly Radiation Therapy (SHORT) for Prostate Cancer.
Mallick I; Arunsingh M; Chakraborty S; Arun B; Prasath S; Roy P; Dabkara D; Achari R; Chatterjee S; Gupta S
Clin Oncol (R Coll Radiol); 2020 Feb; 32(2):e39-e45. PubMed ID: 31551125
[TBL] [Abstract][Full Text] [Related]
37. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).
Pepin A; Aghdam N; Shah S; Kataria S; Tsou H; Datta S; Danner M; Ayoob M; Yung T; Lei S; Gurka M; Collins BT; Krishnan P; Suy S; Hankins R; Lynch JH; Collins SP
Front Oncol; 2020; 10():555. PubMed ID: 32432033
[No Abstract] [Full Text] [Related]
38. Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.
Gallagher L; Xiao J; Hsueh J; Shah S; Danner M; Zwart A; Ayoob M; Yung T; Simpson T; Fallick M; Kumar D; Leger P; Dawson NA; Suy S; Collins SP
Front Oncol; 2023; 13():1289249. PubMed ID: 37916156
[TBL] [Abstract][Full Text] [Related]
39. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results.
Bolzicco G; Favretto MS; Scremin E; Tambone C; Tasca A; Guglielmi R
Technol Cancer Res Treat; 2010 Oct; 9(5):473-7. PubMed ID: 20815418
[TBL] [Abstract][Full Text] [Related]
40. Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT).
Shah S; Pepin A; Forsthoefel M; Burlile J; Collins BT; Simeng S; Aghdam N; Collins S
Cureus; 2023 Aug; 15(8):e44440. PubMed ID: 37791195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
